PDO Based Drug Sensitive Test in R/M HNSCC

Summary

To evaluate the consistency of drug efficacy between the clinical systemic treatment and drug sensitive test based on patient-derived organoid in R/M HNSCC patients, using a prospective and multicenter observational study to increase the generalizability and reliability of research conclusion.

Conditions

• Head and Neck Squamous Cell Carcinoma
• Patient Derived Organoid
• Drug Sensitive Test in Vitro

Interventions

OTHER

No intervention

The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.

OTHER

No Intervention: Observational Cohort

The patients with R/M HNSCC would receive drug treatment according to the clinical guideline or doctor's experience, at the same time, tumor biopsy samples would be collected to establish PDO for drug sensitive test. But no intervention would be used based on the PDO drug sensitive test.

Sponsors & Collaborators

• Shanghai Cancer Hospital, China

  collaborator OTHER

• Eye & ENT Hospital of Fudan University

  collaborator OTHER

• Dongfang Hospital Affiliated to Tongji University

  collaborator OTHER

• Shandong Cancer Hospital and Institute

  collaborator OTHER

• Qilu Hospital of Shandong University

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

  collaborator OTHER

• Tongji Hospital

  collaborator OTHER

• Hospital of Stomatology, Wuhan University

  collaborator OTHER

• Second Affiliated Hospital, School of Medicine, Zhejiang University

  collaborator OTHER

• First Affiliated Hospital of Zhejiang University

  collaborator OTHER

• Sir Run Run Shaw Hospital

  collaborator OTHER

• Zhejiang Cancer Hospital

  collaborator OTHER

• Shanghai Zhongshan Hospital

  collaborator OTHER

• Shanghai Huangpu District Central Hospital

  collaborator UNKNOWN

• Huashan Hospital

  lead OTHER

Principal Investigators

• Lai-ping Zhong, MD, PhD · Huashan Hospital

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-03-26

Primary Completion

2026-11-11

Completion

2028-11-11

Countries

• China

Study Locations